Kangtai Biological (300601.SZ) announced today that it has received a notice of acceptance issued by the National Medical Products Administration, agreeing to accept the clinical trial application of a quadrivalent influenza virus split vaccine (MDCK cells) developed by the company and Lanzhou Biotech Co., Ltd.
The quadrivalent influenza virus split vaccine (MDCK cells) that has been accepted for clinical trials in this application is suitable for people aged 3 and above. It can stimulate the body to produce immunity against influenza viruses and is used to prevent epidemic influenza caused by vaccine-related strains of influenza viruses.